If participant is found to be eligible to take part in this study, participant will receive dabrafenib and trametinib for 8 weeks and then participant will have surgery. Participant will not have surgery if the disease has grown or spread during the 8 weeks participant has received the study drugs. After participant has recovered from surgery and are eating and drinking normally, participant will continue taking the study drugs for up to an additional 44 weeks.